The drug lecanemab slowed the rate of cognitive decline among people with early Alzheimer's disease by 27 per cent, compared with placebo infusions, but some question if its potential safety concerns outweigh any benefits
Eisai has presented and published full data from the Phase 3 clinical trial for its Alzheimer’s disease drug lecanemab, with results showing a statistically significant slowing decline associated with the neurodegenerative disorder. While an accelerated approval decision is expected in early 2023, the latest trial data are key because they represent the confirmatory study that could support an application for full FDA approval.
Despite decades of research and billions of dollars, no treatment has ever definitively proven to slow the progression of Alzheimer’s disease. Two pharmaceutical companies have developed a drug that they say does just that.
/PRNewswire/ Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker findings from the company s.